Impacto de las alertas farmacoterapéuticas sobre la prescripción de clopidogrel e inhibidores de la bomba de protones en pacientes ingresados
Estimar el cambio en la frecuencia de la prescripción de clopidogrel combinado con inhibidores de la bomba de protones (IBP) en pacientes ingresados por enfermedad circulatoria, tras la aparición de alertas relacionadas con su asociación. Identificar la magnitud de la asociación de los factores que...
Saved in:
Published in | Farmacia hospitalaria Vol. 36; no. 4; pp. 250 - 255 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | Spanish |
Published |
Elsevier Espana
01.07.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Estimar el cambio en la frecuencia de la prescripción de clopidogrel combinado con inhibidores de la bomba de protones (IBP) en pacientes ingresados por enfermedad circulatoria, tras la aparición de alertas relacionadas con su asociación. Identificar la magnitud de la asociación de los factores que se relacionaron con la prescripción conjunta.
Estudio observacional, analítico, longitudinal y retrospectivo en el que se evaluaron los cambios de prescripción de la asociación clopidogrel-IBP antes y después de la primera alerta oficial publicada. Se seleccionaron los pacientes que presentaron en el conjunto mínimo básico de datos (CMBD) algún código que incluyera enfermedad del sistema circulatorio, a los que se les prescribió durante su ingreso clopidogrel. Se registró el consumo concomitante de IBP (omeprazol y pantoprazol) en estos pacientes.
Ingresaron 5.678 pacientes con diagnóstico de enfermedad circulatoria, de los que 13,6% llevaron clopidogrel durante el ingreso. En la fase prealerta la prescripción combinada fue significativamente mayor (80,8 vs 48,6). La prescripción conjunta disminuyó si el diagnóstico circulatorio fue el motivo principal de ingreso, si la enfermedad fue cardiaca, si el servicio médico de ingreso fue medicina interna/cardiología o medicina intensiva y cuantas más semanas transcurrieron tras la alerta.
Ha disminuido la prescripción conjunta desde la primera alerta; sobre todo si el motivo de ingreso principal era circulatorio cardiaco y en el caso de omeprazol, que inhibe en mayor grado que pantoprazol el CYP2C19. Los servicios médicos más relacionados con las enfermedades circulatorias se adhieren más a las directrices de las alertas.
to estimate the frequency of clopidogrel prescriptions in association with proton pump inhibitors (PPIs) in patients hospitalised with circulatory pathologies, after the publication of several warnings about this association. To identify and quantify the magnitude of the factors related to the prescription of both drugs.
observational, analytical, longitudinal, and retrospective study assessing changes in prescription of clopidogrel-PPIs association after and before the first official warning (about these drugs’ interactions) was published. We selected all patients with a code indicating a circulatory system disease in the Minimum Basic Data Set, who had been prescribed clopidogrel during hospital admission. We also evaluated proton pump inhibitor use in these patients (omeprazole and pantoprazole).
5678 patients diagnosed with circulatory diseases were admitted during 2009, and clopidogrel was prescribed in 13.6% of them. In the pre-warning period, clopidogrel-PPIs prescriptions were significantly higher than in the post-warning period (80, 8% vs 48, 6%), especially in omeprazole. The combined prescription was lower if the circulatory diagnosis was the main cause for hospitalisation, if the patient had heart disease, if the patient was admitted in Internal Medicine/Cardiology or Intensive care units, and if the period of time was further from warning.
combined prescription has decreased since the first warning, above all in patients with a primary circulatory heart disease. Omeprazole is a potent CYP2C19 inhibitor, so it was used in lower rates than pantoprazole in association with clopidogrel. Medical departments related to cardiovascular disease followed the warning more than others. |
---|---|
AbstractList | Estimar el cambio en la frecuencia de la prescripción de clopidogrel combinado con inhibidores de la bomba de protones (IBP) en pacientes ingresados por enfermedad circulatoria, tras la aparición de alertas relacionadas con su asociación. Identificar la magnitud de la asociación de los factores que se relacionaron con la prescripción conjunta.
Estudio observacional, analítico, longitudinal y retrospectivo en el que se evaluaron los cambios de prescripción de la asociación clopidogrel-IBP antes y después de la primera alerta oficial publicada. Se seleccionaron los pacientes que presentaron en el conjunto mínimo básico de datos (CMBD) algún código que incluyera enfermedad del sistema circulatorio, a los que se les prescribió durante su ingreso clopidogrel. Se registró el consumo concomitante de IBP (omeprazol y pantoprazol) en estos pacientes.
Ingresaron 5.678 pacientes con diagnóstico de enfermedad circulatoria, de los que 13,6% llevaron clopidogrel durante el ingreso. En la fase prealerta la prescripción combinada fue significativamente mayor (80,8 vs 48,6). La prescripción conjunta disminuyó si el diagnóstico circulatorio fue el motivo principal de ingreso, si la enfermedad fue cardiaca, si el servicio médico de ingreso fue medicina interna/cardiología o medicina intensiva y cuantas más semanas transcurrieron tras la alerta.
Ha disminuido la prescripción conjunta desde la primera alerta; sobre todo si el motivo de ingreso principal era circulatorio cardiaco y en el caso de omeprazol, que inhibe en mayor grado que pantoprazol el CYP2C19. Los servicios médicos más relacionados con las enfermedades circulatorias se adhieren más a las directrices de las alertas.
to estimate the frequency of clopidogrel prescriptions in association with proton pump inhibitors (PPIs) in patients hospitalised with circulatory pathologies, after the publication of several warnings about this association. To identify and quantify the magnitude of the factors related to the prescription of both drugs.
observational, analytical, longitudinal, and retrospective study assessing changes in prescription of clopidogrel-PPIs association after and before the first official warning (about these drugs’ interactions) was published. We selected all patients with a code indicating a circulatory system disease in the Minimum Basic Data Set, who had been prescribed clopidogrel during hospital admission. We also evaluated proton pump inhibitor use in these patients (omeprazole and pantoprazole).
5678 patients diagnosed with circulatory diseases were admitted during 2009, and clopidogrel was prescribed in 13.6% of them. In the pre-warning period, clopidogrel-PPIs prescriptions were significantly higher than in the post-warning period (80, 8% vs 48, 6%), especially in omeprazole. The combined prescription was lower if the circulatory diagnosis was the main cause for hospitalisation, if the patient had heart disease, if the patient was admitted in Internal Medicine/Cardiology or Intensive care units, and if the period of time was further from warning.
combined prescription has decreased since the first warning, above all in patients with a primary circulatory heart disease. Omeprazole is a potent CYP2C19 inhibitor, so it was used in lower rates than pantoprazole in association with clopidogrel. Medical departments related to cardiovascular disease followed the warning more than others. |
Author | Valenzuela Gámez, J.C. Sánchez Ruiz-Gordoa, M. Tenías Burillo, J.M. Ruiz Martín de la Torre, R. |
Author_xml | – sequence: 1 givenname: M. surname: Sánchez Ruiz-Gordoa fullname: Sánchez Ruiz-Gordoa, M. email: msanchezruizdegordoa@yahoo.es organization: Farmacia Hospitalaria, Hospital General La Mancha Centro, Alcázar de San Juan, Ciudad Real, España – sequence: 2 givenname: J.M. surname: Tenías Burillo fullname: Tenías Burillo, J.M. organization: Unidad de Apoyo a la Investigación, Área IDF, Hospital General La Mancha Centro, Alcázar de San Juan, Ciudad Real, España – sequence: 3 givenname: R. surname: Ruiz Martín de la Torre fullname: Ruiz Martín de la Torre, R. organization: Farmacia Hospitalaria, Hospital General La Mancha Centro, Alcázar de San Juan, Ciudad Real, España – sequence: 4 givenname: J.C. surname: Valenzuela Gámez fullname: Valenzuela Gámez, J.C. organization: Farmacia Hospitalaria, Hospital General La Mancha Centro, Alcázar de San Juan, Ciudad Real, España |
BookMark | eNp9kEtOwzAQhr0oEm3hBGx8gYRxHk6yYIEqHpUqsYG15ccEXCVxZAckTsE5WHOEXgynZc1qHprvn5l_RRaDG5CQKwYpA8av92krfS_TDBhLoU4BsgVZMpZDwvMiPyerEPYAZVZlbEm-tv0o9eSoQdrJQGWHforxqKHdhF6Oh-_3yerYDE75eYyOHoP2dtT28DPMqO7caI179dhRpHZ4syqWceqkS5XrlZzz0bsp3hsoDjQutjhMsbBDJIM0LlyQs1Z2AS__4pq83N89bx6T3dPDdnO7SzTjTZZwaOoaGwYFKix0bZqcK57VrFS8rnLJmkoWpgDdVExxgw2vWAOtLsvSaFAsX5P8pKu9C8FjK0Zve-k_BQMx-yj24uiBmH0UUIvoY6RuThTG0z4sehHmFzQa61FPwjj7L_8LoW-Eow |
Cites_doi | 10.1111/j.1538-7836.2006.02162.x 10.1177/0091270008315310 10.1016/j.amjcard.2009.10.063 10.1016/S0140-6736(09)61562-2 10.7326/0003-4819-153-6-201009210-00011 10.1001/archinte.166.3.338 10.1016/j.jacc.2008.08.002 10.1161/circ.118.suppl_18.S_815-a 10.1016/j.jacc.2007.06.064 10.1001/jama.287.19.2504-a 10.1161/circ.118.suppl_18.S_815 |
ContentType | Journal Article |
Copyright | 2011 SEFH |
Copyright_xml | – notice: 2011 SEFH |
DBID | AAYXX CITATION |
DOI | 10.1016/j.farma.2011.08.002 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Impact of pharmacotherapeutic warnings on the prescription of clopidogrel and proton pump inhibitors in hospitalised patients |
EndPage | 255 |
ExternalDocumentID | 10_1016_j_farma_2011_08_002 S1130634311001991 |
GroupedDBID | --K 0R~ 2WC 4.4 53G 5GY 5VS AAEDT AALRI AAWTL AAXUO ABXHO ACGFS ADBBV ADCUG AEKER AITUG ALMA_UNASSIGNED_HOLDINGS AMRAJ APOWU AZFZN BAWUL BCNDV DIK E3Z EBS EJD FDB FNPLU GROUPED_DOAJ GX1 HZ~ IPNFZ M41 O-L O9- OK1 P-8 P-9 RIG ROL RSK SCD SDF SES Z7D 0SF AAYXX ADVLN AKRWK CITATION |
ID | FETCH-LOGICAL-c1692-60988e9104ebe4c8d936b62815b6873a197a4d40c971b6de967190fc555dc0b13 |
ISSN | 1130-6343 |
IngestDate | Fri Aug 23 03:54:30 EDT 2024 Fri Feb 23 02:24:57 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Warning Interacción Clopidogrel Alerta Proton pump inhibitors Inhibidores de la bomba de protones Drug-drug interaction |
Language | Spanish |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1692-60988e9104ebe4c8d936b62815b6873a197a4d40c971b6de967190fc555dc0b13 |
OpenAccessLink | https://doi.org/10.1016/j.farma.2011.08.002 |
PageCount | 6 |
ParticipantIDs | crossref_primary_10_1016_j_farma_2011_08_002 elsevier_sciencedirect_doi_10_1016_j_farma_2011_08_002 |
PublicationCentury | 2000 |
PublicationDate | July-August 2012 |
PublicationDateYYYYMMDD | 2012-07-01 |
PublicationDate_xml | – month: 07 year: 2012 text: July-August 2012 |
PublicationDecade | 2010 |
PublicationTitle | Farmacia hospitalaria |
PublicationYear | 2012 |
Publisher | Elsevier Espana |
Publisher_xml | – name: Elsevier Espana |
References | Bhatt, Scheiman, Abraham, Antman, Chan, Furberg (bib0005) 2008; 52 Servicio de Farmacia La Mancha Centro. Página web. Disponible en Gaglia, Torguson, Hanna, Gonzalez, Collins, Syed Al (bib0050) 2010; 105 and Prilosec OTC) [17 Nov 2009]. Aubert, Epstein, Teagarden, Xia, Yao, Desta (bib0035) 2008; 118 Horlen, Malone, Bryant, Dennis, Carey, Pignone (bib0100) 2002; 287 Gilard, Arnaud, Le, Abgrall, Boschat (bib0020) 2006; 4 Bhatt DL, Gyer B, Charles F, Cohen M, Lanas A, Schnitzer TJ, et al. COGENT: a prospective, randomized, placebo-controlled trial. TCT 2009 Meeting San Francisco, California. 24/09/2009. Disponible en Aquino, Brophy (bib0085) 2010; 153 Lasser, Seger, Yu, Karson, Fiskio, Seger (bib0095) 2006; 166 Gilard, Arnaud, Cornily, Le, Lacut, Le (bib0025) 2008; 51 Agencia Española de Medicamentos y Productos Sanitarios AEMPS. Posible interacción de clopidogrel con los inhibidores de la bomba de protones [3 Jun 2009]. Disponible en Sibbing, Kastrati (bib0055) 2009; 374 Food and Drugs Administration. Information for healthcare profesionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix Inhibidores de la bomba de protones: ¿se puede vivir sin ellos? Boletín INFAC. 2010;18:3. Disponible en Dunn, Macaulay, Brennan, Campbell, Charnigo, Smyth (bib0040) 2008; 118 Small, Farid, Pauyne, Weerakkody, Li, Brandt (bib0030) 2008; 48 Ricci, Coulen, Berger, Moore, McQueen Ajan (bib0090) 2009; 15 Latour (bib0010) 2009; 9 European Medicines Agency. Interaction between clopidogrel and proton pump ihibitors [17 Mar 2010]. Disponible en AEMPS. Interacción de clopidogrel con los inhibidores de la bomba de protones: actualización de la información y recomendaciones de uso [27 Abril 2010]. Disponible en to alert heathcare professionals about a drug interaction with omeprazole (marketed as Prilosec Dunn (10.1016/j.farma.2011.08.002_bib0040) 2008; 118 Gilard (10.1016/j.farma.2011.08.002_bib0020) 2006; 4 Horlen (10.1016/j.farma.2011.08.002_bib0100) 2002; 287 10.1016/j.farma.2011.08.002_bib0080 Gaglia (10.1016/j.farma.2011.08.002_bib0050) 2010; 105 Latour (10.1016/j.farma.2011.08.002_bib0010) 2009; 9 10.1016/j.farma.2011.08.002_bib0060 10.1016/j.farma.2011.08.002_bib0070 Lasser (10.1016/j.farma.2011.08.002_bib0095) 2006; 166 Aquino (10.1016/j.farma.2011.08.002_bib0085) 2010; 153 10.1016/j.farma.2011.08.002_bib0015 Aubert (10.1016/j.farma.2011.08.002_bib0035) 2008; 118 Sibbing (10.1016/j.farma.2011.08.002_bib0055) 2009; 374 Bhatt (10.1016/j.farma.2011.08.002_bib0005) 2008; 52 10.1016/j.farma.2011.08.002_bib0075 Gilard (10.1016/j.farma.2011.08.002_bib0025) 2008; 51 10.1016/j.farma.2011.08.002_bib0065 Small (10.1016/j.farma.2011.08.002_bib0030) 2008; 48 10.1016/j.farma.2011.08.002_bib0045 Ricci (10.1016/j.farma.2011.08.002_bib0090) 2009; 15 |
References_xml | – volume: 9 start-page: A98 year: 2009 ident: bib0010 article-title: ¿Debemos abandoner el uso conjunto de clopidogrel e inhibidores de la bomba de protones? publication-title: REMI contributor: fullname: Latour – volume: 287 start-page: 2504 year: 2002 end-page: 2505 ident: bib0100 article-title: Research letter: frequency of inappropriate metformin prescriptions publication-title: JAMA contributor: fullname: Pignone – volume: 4 start-page: 2508 year: 2006 end-page: 2509 ident: bib0020 article-title: Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin publication-title: J Thromb Haemost contributor: fullname: Boschat – volume: 118 start-page: S815 year: 2008 ident: bib0040 article-title: Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREEDO trial (Abstract) publication-title: Circulation contributor: fullname: Smyth – volume: 153 start-page: 413 year: 2010 end-page: 415 ident: bib0085 article-title: Conflicting evidence- what is a clinician to do? publication-title: Ann Intern Med contributor: fullname: Brophy – volume: 374 start-page: 952 year: 2009 end-page: 953 ident: bib0055 article-title: Risk of combining PPIs with thienopyridines: fact or fiction? publication-title: Lancet contributor: fullname: Kastrati – volume: 51 start-page: 256 year: 2008 end-page: 260 ident: bib0025 article-title: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study publication-title: J Am Coll Cardiol contributor: fullname: Le – volume: 52 start-page: 1502 year: 2008 end-page: 1517 ident: bib0005 article-title: ACCF/ACG/AHA Expert consensus document on reducing the gastrointestinal risk of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents publication-title: J Am Coll Cardiol contributor: fullname: Furberg – volume: 105 start-page: 833 year: 2010 end-page: 838 ident: bib0050 article-title: Relation of Proton Pump Inhibitors use after percutaneous coronary intervention with drug-eluting stents to outcomes publication-title: Am J Cardiol contributor: fullname: Syed Al – volume: 48 start-page: 475 year: 2008 end-page: 484 ident: bib0030 article-title: Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel publication-title: J Clin Pharmacol contributor: fullname: Brandt – volume: 166 start-page: 338 year: 2006 end-page: 344 ident: bib0095 article-title: Adherence to black box warnings for prescription medications in outpatients publication-title: Arch Intern Med contributor: fullname: Seger – volume: 15 start-page: 103 year: 2009 end-page: 108 ident: bib0090 article-title: Prescriber compliance with black box warnings in older adults patients publication-title: Am J Manag Care contributor: fullname: McQueen Ajan – volume: 118 start-page: S815 year: 2008 ident: bib0035 article-title: Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel medco outcomes study (Abstract) publication-title: Circulation contributor: fullname: Desta – volume: 4 start-page: 2508 year: 2006 ident: 10.1016/j.farma.2011.08.002_bib0020 article-title: Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.02162.x contributor: fullname: Gilard – volume: 48 start-page: 475 year: 2008 ident: 10.1016/j.farma.2011.08.002_bib0030 article-title: Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel publication-title: J Clin Pharmacol doi: 10.1177/0091270008315310 contributor: fullname: Small – volume: 105 start-page: 833 year: 2010 ident: 10.1016/j.farma.2011.08.002_bib0050 article-title: Relation of Proton Pump Inhibitors use after percutaneous coronary intervention with drug-eluting stents to outcomes publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2009.10.063 contributor: fullname: Gaglia – volume: 374 start-page: 952 year: 2009 ident: 10.1016/j.farma.2011.08.002_bib0055 article-title: Risk of combining PPIs with thienopyridines: fact or fiction? publication-title: Lancet doi: 10.1016/S0140-6736(09)61562-2 contributor: fullname: Sibbing – volume: 153 start-page: 413 year: 2010 ident: 10.1016/j.farma.2011.08.002_bib0085 article-title: Conflicting evidence- what is a clinician to do? publication-title: Ann Intern Med doi: 10.7326/0003-4819-153-6-201009210-00011 contributor: fullname: Aquino – volume: 166 start-page: 338 year: 2006 ident: 10.1016/j.farma.2011.08.002_bib0095 article-title: Adherence to black box warnings for prescription medications in outpatients publication-title: Arch Intern Med doi: 10.1001/archinte.166.3.338 contributor: fullname: Lasser – ident: 10.1016/j.farma.2011.08.002_bib0065 – volume: 52 start-page: 1502 year: 2008 ident: 10.1016/j.farma.2011.08.002_bib0005 article-title: ACCF/ACG/AHA Expert consensus document on reducing the gastrointestinal risk of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2008.08.002 contributor: fullname: Bhatt – ident: 10.1016/j.farma.2011.08.002_bib0060 – ident: 10.1016/j.farma.2011.08.002_bib0045 – ident: 10.1016/j.farma.2011.08.002_bib0080 – volume: 118 start-page: S815 year: 2008 ident: 10.1016/j.farma.2011.08.002_bib0040 article-title: Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREEDO trial (Abstract) publication-title: Circulation doi: 10.1161/circ.118.suppl_18.S_815-a contributor: fullname: Dunn – volume: 9 start-page: A98 year: 2009 ident: 10.1016/j.farma.2011.08.002_bib0010 article-title: ¿Debemos abandoner el uso conjunto de clopidogrel e inhibidores de la bomba de protones? publication-title: REMI contributor: fullname: Latour – volume: 51 start-page: 256 year: 2008 ident: 10.1016/j.farma.2011.08.002_bib0025 article-title: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2007.06.064 contributor: fullname: Gilard – ident: 10.1016/j.farma.2011.08.002_bib0015 – volume: 15 start-page: 103 year: 2009 ident: 10.1016/j.farma.2011.08.002_bib0090 article-title: Prescriber compliance with black box warnings in older adults patients publication-title: Am J Manag Care contributor: fullname: Ricci – volume: 287 start-page: 2504 year: 2002 ident: 10.1016/j.farma.2011.08.002_bib0100 article-title: Research letter: frequency of inappropriate metformin prescriptions publication-title: JAMA doi: 10.1001/jama.287.19.2504-a contributor: fullname: Horlen – volume: 118 start-page: S815 year: 2008 ident: 10.1016/j.farma.2011.08.002_bib0035 article-title: Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel medco outcomes study (Abstract) publication-title: Circulation doi: 10.1161/circ.118.suppl_18.S_815 contributor: fullname: Aubert – ident: 10.1016/j.farma.2011.08.002_bib0070 – ident: 10.1016/j.farma.2011.08.002_bib0075 |
SSID | ssj0052721 |
Score | 1.8142573 |
Snippet | Estimar el cambio en la frecuencia de la prescripción de clopidogrel combinado con inhibidores de la bomba de protones (IBP) en pacientes ingresados por... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | 250 |
SubjectTerms | Alerta Clopidogrel Drug-drug interaction Inhibidores de la bomba de protones Interacción Proton pump inhibitors Warning |
Title | Impacto de las alertas farmacoterapéuticas sobre la prescripción de clopidogrel e inhibidores de la bomba de protones en pacientes ingresados |
URI | https://dx.doi.org/10.1016/j.farma.2011.08.002 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbpwwELZW6aWXqr9q-icfqlxYEBgw-NikzaaRUkXVptobwtgoGzUQhd1D9iX6HD33EfJAfYXO2PypiaKmF4RgMIb5sGeGmc-EvGc54zljiZvLqHSjSElXpn7pxiCvC-VzVWJo4OgLPziJDhfxYjL5PcpaWq-kV2xurSv5H63CMdArVsneQ7N9o3AA9kG_sAUNw_afdPzZlDjWjtIOGMEOjPVgSzdOadmosbb4wv4INxHrxmlqcIBBFJkBzHBRLPH8bogZsU6BxVOqBgf8u4NUIqdYmFeDpG3fkfW5zHEfuR2Q4t_B_K7cVFSatC503XNVN2ODd9_0ZZk7p-0CJbnNa7ZhHdO7oALgbJyv6-XGnYEvXBt79sjrgwowMqLcR3iC3fXlsvtb5A0ieC2WHa2sYNX2eI5LjxgQ9ZLf4CVVm7WGszN793MbQz_09rxxCCQY0mW7URsmYpeHlu-pG9Ytr0oL32g8Rlum23a6Z5Yl-MZMYoMaZ55R2UD16rNh4uySBf6aT_ssxy6B7iwzjWTYSIaLfiL56QOWiBijBbNFn5MUs8QWCnbP09FkmYTEGz253ZQamUfzx-RR69fQDxakT8hEN0_JzrElRr-a0vlQ59dM6Q49HijTr56RHy2SqdIUkExbJNMxkq9_WhRTg2IQowOKr39VeOkIwVTTEYJtu9QgGPc7BFNd0R7BdEDwc3Ky_2m-d-C2S4W4RcAFc7kv0lSD6RvBoBQVqRIhl5ylQSx5moR5IJI8UpFfiCSQXGnBE7CEyyKOY1X4MghfkK0K7vuSUOlrEZZahQqcdSZSKUoVgB-ihGIiLvg2mXZvPbuwjDDZHZreJrzTTNYatdZYzQBpd1346n73eU0eDp_GG7K1ulzrt2Avr-Q7g7E_7TbEKw |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impacto+de+las+alertas+farmacoterap%C3%A9uticas+sobre+la+prescripci%C3%B3n+de+clopidogrel+e+inhibidores+de+la+bomba+de+protones+en+pacientes+ingresados&rft.jtitle=Farmacia+hospitalaria&rft.au=S%C3%A1nchez+Ruiz-Gordoa%2C+M.&rft.au=Ten%C3%ADas+Burillo%2C+J.M.&rft.au=Ruiz+Mart%C3%ADn+de+la+Torre%2C+R.&rft.au=Valenzuela+G%C3%A1mez%2C+J.C.&rft.date=2012-07-01&rft.issn=1130-6343&rft.volume=36&rft.issue=4&rft.spage=250&rft.epage=255&rft_id=info:doi/10.1016%2Fj.farma.2011.08.002&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_farma_2011_08_002 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1130-6343&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1130-6343&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1130-6343&client=summon |